Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 9/20 | 0.41 |
| ▸ | MAOB | P27338 | 8/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | CALML3 | P27482 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | SDHA | P31040 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752375 | 1.00 | MAOA (0.41) | MAOAMAOBKCNH2CALML3CYP3A4 | |
| SCHEMBL14024107 | 0.88 | MAOA (0.41) | MAOAMAOBKCNH2CALML3CYP3A4 | |
| SCHEMBL3758147 | 0.88 | MAOA (0.44) | MAOAMAOBKCNH2CALML3CYP3A4 | |
| SCHEMBL13054641 | 0.88 | MAOA (0.44) | MAOAMAOBKCNH2CALML3CYP3A4 | |
| SCHEMBL3748036 | 0.85 | MAOB (0.49) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL3759941 | 0.85 | MAOB (0.45) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL13054713 | 0.85 | MAOB (0.49) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL3760724 | 0.84 | MAOB (0.47) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL3758599 | 0.83 | MAOA (0.57) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL13054642 | 0.83 | MAOA (0.57) | MAOAMAOBCALML3LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298384-A1 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298384-A1 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-11-25 | — | — | US | disclosed |
| WO-2008143649-A2 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298384-A1 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | OXA1L, MIF, VIP | MAOA 3034/4885MAOB 2709/4885KCNH2 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.